>>SUNNYVALE, Calif., Sept. 4 /PRNewswire/ -- Scios Inc. (Nasdaq: SCIO - news) announced today that researchers presented data derived from its PRECEDENT (Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Nesiritide Therapy) trial at the 23rd Congress of the European Society of Cardiology meeting in Stockholm. Researchers discussed the effects of gender differences, diabetes history and other factors on the treatment and outcome of congestive heart failure patients.
``Additional analyses of data from the PRECEDENT trial should substantially increase the information available to physicians and help them make more informed treatment decisions for their congestive heart failure patients,'' said Darlene P. Horton, M.D., vice president of medical affairs for Scios.
The PRECEDENT study was a randomized, multicenter trial evaluating the safety and efficacy of nesiritide (human B-type natriuretic peptide) compared to dobutamine in patients with acutely decompensated congestive heart failure.
The three abstracts presented at the meeting were:
-- Aronson D, Horton D, Burger AJ. Gender Differences in the Occurrence
of Ventricular Ectopy in Patients with Congestive Heart Failure.
-- Burger AJ, Horton D, Aronson D. Blunted Sympathetic Response in
Diabetic Patients with Decompensated Congestive Heart Failure.
-- Burger AJ, Horton D, Aronson D. The Effect of Dobutamine on
Neurohormonal and Cytokine Profiles in Patients with Decompensated
Congestive Heart Failure.<<
snip
Cheers, Tuck |
